Lupin has posted a strong Q4FY25 led by momentum in its US portfolio, with ICICI Securities reaffirming a HOLD recommendation and a target price of Rs 2,110, indicating limited upside from the curr

Sanofi, the French pharmaceutical heavyweight, has earned a reaffirmed BUY rating from Morningstar as of May 2025.

Choice Equity Broking has initiated a "BUY" call on Laurus Labs with a target price of Rs 750, projecting a 16% upside from current levels.

Sun Pharmaceutical Industries has received a favorable legal ruling in the United States that clears a key hurdle in launching Leqselvi, its much-anticipated treatment for alopecia areata.

Cipla has received a reaffirmed ‘BUY’ rating from Prabhudas Lilladher following a pivotal regulatory development—the USFDA approval of its generic version of Abraxane (gAbraxane).

In a sharp divergence from its pandemic-era highs, Moderna Incorporated finds itself trading at a substantial discount, even as it sharpens focus on a curated pipeline of mRNA-based therapies.